bioMerieux : Q1 2024 sales in line with the consensus– Guidance maintained – CMD and announcement of a 5-year plan (robust growth/margin improvement)
>Q1 2024 sales: +10% l-f-l. - Q1 sales came to € 965m (+6.6% and +9.8% l-f-l.). Clinical applications were up 7.7% (+10.7% l-f-l) and industrial applications grew 0.8% (+5.3% l-f-l).For 2024, the management reiterated its guidance (growth of 6-8% for c.Ebit up 10% l-f-l (€ 670m) though with an FX effect of -€ 50m, or € 621m at the mid-point of estimated sales). The consensus forecast is for € 3,903m, +7.6% organic. (sales: € 3,903m est. - cEBIT: min-max: € 626m...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.